Protocol Ledger

NCT05744375 · Phase II · TERMINATED

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab

Interventional Phase II clinical trial protocol NCT05744375 sponsored by Spanish Breast Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-28 Enrollment: 2 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05744375
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05744375
Protocol FieldVerified Registry Value
NCT IdentifierNCT05744375
Consolidated Lead SponsorSpanish Breast Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment2 participants (ACTUAL)
Registered Start Date2023-09-28
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05744375
Hospital Research SiteLocationSite Profile
Hospital Universitario Marqués de ValdecillaSantander, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI